In a continued effort to help fight the COVID-19 crisis, Eurofins Technologies announces the CE-IVD marking of a first range of testing kits for serology-based antibody detection by ELISA of patients who have been exposed to COVID-19. The development of the assays has been spearheaded by affiliate companies Gold Standard Diagnostics Inc., VIROTECH Diagnostics GmbH, NovaTec Immundiagnostica GmbH and Ingenasa (Inmunologia Y Genetica Aplicada SA). Those specialized diagnostic technologies companies are well-established providers of testing solutions with a strong focus on scientific excellence in infectious diseases testing and immunology.
Serologic kits detect antibodies in patients exposed to COVID-19
Tags: SARS-CoV-2, COVID-19, CE-IVD, Serology based antibody
Eurofins Genomics launches “SARS-CoV-2 Full-length Genome Sequencing”
SARS-CoV-2 Full-length Genome Sequencing” service to support researchers globally in their fight against the COVID-19 pandemic and outbreak source tracing
Ebersberg, Germany - Eurofins Genomics Europe, a leader in genomic products and services, announces the launch of its “SARS-CoV-2 Full-length Genome Sequencing” service, a new next generation sequencing (NGS) service enabling end-to-end surveillance of the coronavirus genome sequence and mutational drift. The new service is Eurofins Genomics’ latest addition to a whole product portfolio aimed at supporting researchers globally in their fight against the COVID-19 pandemic.
Tags: SARS-CoV-2, COVID-19, Genome Sequencing